checkAd

     129  0 Kommentare Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)

    • Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension

    MORRISVILLE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the company will present seven posters related to its product pipeline at the 7th World Symposia of Pulmonary Hypertension (WSPH) taking place June 29 to July 1, 2024, in Barcelona, Spain. The posters outlined below address the clinical investigations of Liquidia’s investigational products, YUTREPIA (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension sustained-release formulation to treat people with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

    Rajeev Saggar, MD, Chief Medical Officer at Liquidia, said: “Since 1973, the World Symposia on Pulmonary Hypertension has contributed to the ongoing scientific advancement of our field. We are delighted to present seven thematic posters on the world stage showcasing YUTREPIA and L606. We look forward to initiating a global, pivotal placebo-controlled efficacy trial of L606 in PH-ILD later this year.”

    Liqudia’s posters will be presented on Sunday, June 30, 2024, from 5:15 – 6:30 p.m. CEST and include:

    Live Thematic Poster Sessions

    Abstract B83 – Exploratory Efficacy Analysis of INSPIRE Open Label Extension Study with Inhaled Treprostinil (YUTREPIA). Presented by Savan Patel, Liquidia Technologies.

    Abstract B87 – High Resolution Computed Tomography (HRCT) Chest Scans to Examine the Association Between Regional Drug Deposition of LIQ861 (YUTREPIA) and Vasodilation in PH-ILD Population. Presented by Benjamin Lavon, MS, Fluidda.

    Encore Thematic Poster Sessions

    Abstract B85 - A Phase 3, 2-Part, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects with PAH and PH-ILD. Presented by Michelle Ghofrani, MD, Liquidia Technologies.

    Abstract B86 – Safety and Tolerability of LIQ861 (YUTREPIA) in Pulmonary Arterial Hypertension (PAH): Results from INSPIRE Study. Presented by Savan Patel, Liquidia Technologies.

    Abstract B89 – The ASCENT Study: An Open-Label Prospective Multicenter Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension. Presented by Dawn Fleming, Liquidia Technologies.

    Seite 1 von 4


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH) Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension MORRISVILLE, N.C., June 18, …